Review of etoposide single-agent activity

VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.

1978 • 166 citations

VP-16–213 salvage therapy for refractory germinal neoplasms

1980 • 163 citations

Etoposide (VP-16-213)

1979 • 151 citations

SCHEDULE DEPENDENCY OF THE ANTILEUKEMIC ACTIVITY OF THE PODOPHYLLOTOXIN‐DERIVATIVE VP 16–213 (NSC‐141540) IN L1210 LEUKEMIA

1973 • 148 citations

Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.

1979 • 142 citations

Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas

1974 • 118 citations

Cancer Chemotherapy Handbook.

1980 • 113 citations

VP16-213 as a single agent in advanced testicular tumors

1980 • 112 citations

A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213

1975 • 97 citations

Pyogenic cocci in infantile eczema throughout one year.

1975 • 88 citations

Epipodophyllotoxin VP 16213 in Treatment of Acute Leukaemia--Haematosarcoma and Solid Tumours

1973 • 88 citations

Podophyllotoxin derivative VP 16-213

1979 • 86 citations

Phase II study of VP-16-213 in childhood malignant disease: a Children's Cancer Study Group Report.

1979 • 83 citations

Clinical trial of VP 16–213 (NSC 141540) I.V. Twice weekly in advanced neoplastic disease a study by the cancer and leukemia group B

1980 • 69 citations

Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-D-glucopyranoside)

1977 • 58 citations

Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma.

1977 • 52 citations

VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung.

1978 • 47 citations

VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer.

1976 • 45 citations

Clinical investigation of a new podophyllum derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidene- -D-glucopyranoside) (NSC-122819), in patients with malignant lymphomas and solid tumors.

1972 • 45 citations

A phase II study of oral VP-16-213 in non-seminomatous testicular cancer

1981 • 44 citations

Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213).

1972 • 42 citations

Radiation recall associated with VP-16-213 therapy.

1979 • 39 citations

Activity of the Epipodophyllotoxin VP‐16 in the Treatment of Combination Chemotherapy‐Resistant Non‐Hodgkin Lymphoma

1978 • 35 citations

Evaluation of VP-16-213 in malignant lymphoma and melanoma.

1978 • 34 citations

4'-demethylepipodophyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside) (NSC-122819; VM-26) and 4'-demethylepipodophyllotoxin 9-(4.6-0-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213) in childhood cancer: preliminary observations.

1975 • 33 citations

Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease.

1975 • 30 citations

The role of VP16-213 (Etoposide; NSC-141540) in gestational choriocarcinoma

1982 • 28 citations

Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer.

1979 • 28 citations

Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents

1978 • 27 citations

Comparison of the biologic activity of VP-16-213 given iv and orally in capsules or drink ampules.

1976 • 26 citations

Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer.

1976 • 23 citations

Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213).

1974 • 23 citations

Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer.

1976 • 21 citations

Phase I trial of a new form of an oral administration of VP-16-213.

1979 • 21 citations

Evaluation of VP-16 and the Combination of Adriamycin and Vincristine in Advanced Breast Cancer

1976 • 20 citations

Etoposide (VP 16-213) — a podophyllotoxinderivative with high antitumor activity

1981 • 15 citations

[Initial results with a epipodophyllotoxin derivative VP 16-213 in the treatment of acute leukemia].

1975 • 13 citations

[Therapeutic results using VP 16-213 alone or in combination with 5-fluorouracil in liver cancer (hepatoma)].

1977 • 12 citations

Randomisierte Phase-II-Studie mit VP-16–213 (Etoposide®) in der Behandlung vom fortgeschrittenen Mammakarzinom

1981 • 12 citations

[Therapeutic experiences using the new podophyllotoxin derivative VP 16-213 in malignant human tumors].

1975 • 9 citations

Phase II evaluation of diglycoaldehyde, VP-16-213, and the combination of methyl-CCNU and beta-2'-deoxythioguanosine in previously treated patients with colorectal cancer: an Eastern Cooperative Oncology Group study (EST-1275).

1979 • 8 citations

Incompatibilities with parenteral anticancer drugs

1979 • 7 citations

Erfolgreiche Behandlung der chronischen myelomonozyt�ren Leuk�mie mit VP 16-213

1979 • 5 citations

Chronic myelomonocytic leukaemia: a case report.

1977 • 4 citations

Chronic Myelomonocytic Leukaemia

1977 • 4 citations

VP-16-213: A phase II study of non-small cell lung cancer (NSCLC)

1981 • 3 citations